publication . Article . 2015

Disfuncionalidad antioxidante de las lipoproteínas de alta densidad (hdl) en pacientes diabéticos descompensados

Awad, Fernanda; Contreras-Duarte, Susana; Molina, Patricia; Quiñones, Verónica; Serrano, Valentina; Abbott, Eduardo; Maiz, Alberto; Busso, Dolores; Rigotti, Attilio;
Open Access Spanish; Castilian
  • Published: 01 Sep 2015
  • Country: Chile
Abstract
Introducción: las lipoproteínas de alta densidad (HDL) tienen un importante efecto protector cardiovascular mediado por su función durante el transporte reverso del colesterol, así como por otras actividades, incluyendo una significativa acción antiinflamatoria y antioxidante. La funcionalidad antiinflamatoria y antioxidante de las HDL está alterada en los pacientes diabéticos crónicos estables, aunque no existe mayor información en caso de una crisis hiperglicémica. Objetivo: determinar si durante un estado de descompensación diabética aguda las partículas de HDL exhiben un deterioro de su función antioxidante y si esta logra recuperarse una vez resuelto el cua...
Subjects
free text keywords: Lipoproteínas de alta densidad, Diabetes mellitus, Crisis hiperglicémica, Capacidad antioxidante de HDL, Paraoxonasa-1, High density lipoproteins, Hyperglycemic crisis, Antioxidant capacity of HDL, Paraoxonase-1
20 references, page 1 of 2

1. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 Suppl 1:S81-90.

2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K & Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4): 229-34.

3. Van Linthout S, Spillmann F, Schultheiss HP & Tschope C. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr Pharm Des. 2010; 16(13): 1504-16.

4. Kontush A & Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev. 2006; 58(3): 342-74.

5. Lubrano V, Baldi S, Ferrannini E, L'Abbate A & Natali A. Role of thromboxane A2 receptor on the effects of oxidized LDL on microvascular endothelium nitric oxide, endothelin-1, and IL-6 production. Microcirculation. 2008; 15(6): 543-53.

6. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM & Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995; 96(6): 2758-67.

7. Navab M, Reddy ST, Van Lenten BJ & Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011; 8(4): 222-32.

8. Van Lenten BJ, Navab M, Shih D, Fogelman AM & Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med. 2001; 11(3-4): 155-61.

9. Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, Ferrannini E & Reddy ST. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes. 2011; 60(10): 2617-23.

10. Allain CC, Poon LS, Chan CS, Richmond W & Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20(4): 470-5. [OpenAIRE]

11. Lowry OH, Rosebrough NJ, Farr AL & Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1): 265-75.

12. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM: A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001, 42(8):1308-1317.

13. Murphy AJ & Woollard KJ. High-density lipoprotein: a potent inhibitor of inflammation. Clin Exp Pharmacol Physiol. 2010; 37(7): 710-8.

14. Novak F, Vavrova L, Kodydkova J, Novak F Sr, Hynkova M, Zak A, Novakova O. Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med. 2010; 10(1):21-5.

15. Murakami H, Tanabe J, Tamasawa N, Matsumura K, Yamashita M, Matsuki K, Murakami H, Matsui J & Suda T. Reduction of paraoxonase-1 activity may contribute the qualitative impairment of HDL particles in patients with type 2 diabetes. Diab Res Clin Pract. 2013; 99(1): 30-8.

20 references, page 1 of 2
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2015

Disfuncionalidad antioxidante de las lipoproteínas de alta densidad (hdl) en pacientes diabéticos descompensados

Awad, Fernanda; Contreras-Duarte, Susana; Molina, Patricia; Quiñones, Verónica; Serrano, Valentina; Abbott, Eduardo; Maiz, Alberto; Busso, Dolores; Rigotti, Attilio;